Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top concern as they face growing electricity demand and network complexity. ABI Research's survey highlights that TSOs see software as essential for grid resilience and risk management, with budgets allocated for both operational efficiency and long-term grid transformation. Vendors must focus on security, interoperability, and practical value to meet TSOs' evolving needs.
The topic of software critical for Transmission System Operators (TSOs) to enhance grid resilience is presented here with market context from the Utilities sector on Pluang. For readers following Utilities stocks, as of Oct 14, 2026 19:42 WIB, 22 of 40 priced US Utilities stocks rose while 14 fell. Notable movers include NRG Energy Inc (NRG) at USD 105.86 with a typical hold time of 63 days and a Pluang order activity heavily skewed to 96% Sell, Fluence Energy Inc. Class A (FLNC) at USD 6.70 down 1.18%, and Constellation Energy Corporation (CEG) at USD 292.43 with a balanced order activity of 53% Sell and 47% Buy and a typical hold time of 41 days.
Air Canada will begin a new seasonal nonstop flight service between Montreal and Seville, Spain, starting September 8, 2027. This route is the only nonstop connection between North America and Seville, enhancing travel options for leisure and busines...
Air Canada announced it will start non-stop seasonal flights between Montréal and Seville, Spain, beginning September 8, 2027. This new route is the only direct connection between North America and Seville, enhancing travel options for Canadians and ...
CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...
Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...
Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...
